Suppr超能文献

髓单核细胞抗原很少在B淋巴细胞白血病细胞上表达。

Myelomonocytic antigens are rarely expressed on B-lymphocytic leukemia cells.

作者信息

Polliack A, Rabinowitz R, Leizerowitz R, Keren-Zur Y, Schlesinger M

机构信息

Department of Haematology, Hadassah University Hospital, Jerusalem, Israel.

出版信息

Leuk Lymphoma. 1993 Jan;9(1-2):125-31. doi: 10.3109/10428199309148515.

Abstract

In the light of recent observations reporting that B-lymphocytic leukemia (B-CLL) cells may express a variety of myelomonocytic antigens, 28 patients with B-CLL and B-leukemic lymphocytic lymphoma were studied for the presence of these antigens using monoclonal antibodies to detect CD13, CD33, CD15 and CD14. Analysis of immunofluorescence (IF) was carried out by two procedures; one which employed the standard conventional method of gating used in our laboratory for flow cytometry, while the other procedure increased the sensitivity of the analysis, by moving the marker for IF to the left, so as to widen the gate to include more cells with low IF. Using the conventional methodology, the mean proportion of cells considered positive was less than 3% for any of the 4 markers studied. In only a few patients were 5% or more of the B-CLL cells positive for some of the markers studied (3 patients with 6.2-11.3% CD13+; 2 with 6.0-9.6% CD14+, and one with 11.8% CD15+ cells). No case had more than 2.5% + CD33+ cells. The second procedure with a wider gate to enhance sensitivity for less positive cells, increased the number of positive cells for any of the markers in only 4 patients. These results are contradictory to others reported recently, and some of the possible causes for this discrepancy are discussed. It is suggested that more useful data may be obtained if the level of staining intensity and patterns of positive staining are documented in the future.

摘要

鉴于最近有观察报告称B淋巴细胞白血病(B-CLL)细胞可能表达多种髓单核细胞抗原,我们使用单克隆抗体检测CD13、CD33、CD15和CD14,对28例B-CLL和B淋巴细胞白血病性淋巴瘤患者进行了这些抗原存在情况的研究。免疫荧光(IF)分析通过两种方法进行;一种采用我们实验室用于流式细胞术的标准传统设门方法,而另一种方法通过将IF标记向左移动来提高分析的灵敏度,从而扩大设门范围以纳入更多低IF的细胞。使用传统方法,对于所研究的4种标记物中的任何一种,被视为阳性的细胞平均比例均小于3%。只有少数患者的部分所研究标记物的B-CLL细胞阳性率达到或超过5%(3例患者CD13阳性率为6.2 - 11.3%;2例患者CD14阳性率为6.0 - 9.6%,1例患者CD15阳性细胞率为11.8%)。没有病例的CD33阳性细胞超过2.5%。第二种扩大设门范围以提高对较少阳性细胞灵敏度的方法,仅在4例患者中增加了任何一种标记物的阳性细胞数量。这些结果与最近报道的其他结果相矛盾,本文讨论了造成这种差异的一些可能原因。建议未来如果记录染色强度水平和阳性染色模式,可能会获得更有用的数据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验